Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P299: A novel ileocolonic Crohn’s staging tool: the development and validation of an evidence-based, end-user informed radiological decision-aid

ECCO '19 Copenhagen

Year: 2019
Authors:

P. S. Morar*1,2, K. A. Wasmann3, A. C. T. Fareleira4, K. Sahnan1,2, S. O. Adegbola1,2, E. Mainta1, R. Ilangovan1, S. Arora2, N. Sevdalis5, K. Koysombat1, A. Hart1,2, D. Burling1, C. Edwards6, J. Warusavitarne1,2, A. Gupta1, W. A. Bemelman3, O. Faiz1,2

1St Mark's Hospital, London, UK, 2Imperial College London, London, UK, 3Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, 4Centro Hospitalar S. Joao,, Porto, Portugal, 5King’s College, London, UK, 6South Devon NHS Foundation Trust,, Torbay, UK

P300: Long-term surgical outcomes following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis in a tertiary IBD centre in Brazil

ECCO '19 Copenhagen

Year: 2019
Authors:

R. S. Parra*1, M. R. Feitosa1, F. C. Pereira1, R. S. Rodrigues1, O. Féres1, J. J. Ribeiro da Rocha1

1Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil, Surgery and Anatomy, Ribeirão Preto, SP, Brazil

P301: A serological biomarker of type VIII collagen that contains the anti-angiogenic signalling molecule, vastatin, is associated with the extension of disease in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Lindholm*1,2, L. E. Godskesen2, L. L. Langholm1, J. Kjeldsen2, A. Krag2, M. A. Karsdal1, T. Manon-Jensen1, J. H. Mortensen1

1Nordic Biosciene A/S, Biomarkers and Research, Herlev, Denmark, 2University of Southern Denmark and Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark

P302: Predictors of outcome in children with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

M. T. Fioretti*1, C. Strisciuglio2, M. Martinelli1, P. Dolce3, G. Vallone4, A. Staiano1, E. Miele1

1University of Naples Federico II, Department of Translational Medical Science, Section of Pediatrics, Naples, Italy, 2University of Campania ‘Luigi Vanvitelli’, Department of Woman, Child and General and Specialistic Surgery, Naples, Italy, 3University of Naples Federico II, Public of Health Department, Naples, Italy, 4University of Naples Federico II, Department of Radiology Section of Pediatric Diagnostics, Naples, Italy

P303: Hyperbilirubinemia can be induced with azathioprin treatment in patients with inflammatory bowel disease: a hospital-based cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Moon*1, K. I. Seo1, S. J. Park1, M. I. Park1, S. U. Lee1, B. C. Yun1, B. H. Han1, E. T. Park1, J. H. Kim1, S. E. Kim1, K. Jung1

1Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea

P304: Predicting severity in Crohn's disease

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Gouveia*1, C. Gomes1, L. Glória1, J. Torres1, M. Cravo2

1Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal, 2Hospital Beatriz Ângelo, Gastroenterology, Lisboa, Portugal

P305: Platelet parameters evaluation as a non-invasive marker of inflammation in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Padysz*1, J. Banasik1, A. Gąsiorowska1

1Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz – Central Veterans’ Hospital, Department of Gastroenterology, Lodz, Poland

P306: Double balloon enteroscopy in paediatric Crohn’s disease and 10 years follow-up

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Oba*1,2, A. Carlos3, M. Azevedo3, L. Milani3, N. Freitas4, R. Toma5, M. Bibas5, A. Damião3, A. Safatle-Ribeiro3

1São Paulo University Medical School, Pediatric, São Paulo, Brazil, 2Hospital Israelita Albert Einstein, GI, São Paulo, Brazil, 3Hospital das Clínicas HCFMUSP, Gastroenterology, São Paulo, Brazil, 4Hospital das Clínicas HCFMUSP, Surgery, São Paulo, Brazil, 5Instituto da Criança HCFMUSP, Pediatric, São Paulo, Brazil

P307: The use of the patient safety form in patients with inflammatory bowel disease, can improve the low screening and starting HBV prophylaxis rates in real life

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Demir*1, E. Uçar2, M. M. Çelik2

1Mustafa Kemal University, Gastroenterology, Hatay, Turkey, 2Mustafa Kemal University, Internal Medicine, Hatay, Turkey

P308: Utility of bowel ultrasound in diagnosing disease activity in Crohn’s disease: Indian experience

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Kakkadasam Ramaswamy*1, K. V. Nagarajan1, A. Yelsangikar1, A. Nagar1, N. Bhat1

1Aster CMI Hospital, Department of Gastroenterology, Liver Diseases and Clinical Nutrition, Bangalore, India

P309: Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Marín-Jiménez*1,2, G. Bastida3,4, A. Forés5, E. García-Planella6, F. Argüelles-Arias7, P. Sarasa8, I. Tagarro8, A. Fernández-Nistal8, C. Montoto8, M. Aguas3,4, J. Santos-Fernández9, M. Boscá10, R. Ferreiro-Iglesias11, O. Merino12, X. Aldeguer13, X. Cortés14,15, B. Sicilia16, F. Mesonero17, M. Barreiro-de Acosta11

1Hospital Gregorio Marañón, Department of Gastroenterology, Madrid, Spain, 2Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, 3Hospital La Fe, Valencia, Spain, 4Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Valencia, Spain, 5Hospital General Universitario de Castellón, Castellón, Spain, 6Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 7Hospital Universitario Virgen Macarena, Sevilla, Spain, 8Takeda Farmacéutica España SA, Madrid, Spain, 9Hospital Universitario Río Hortega, Department of Gastroenterology, Valladolid, Spain, 10University Clinic Hospital of Valencia, IBD Unit, Gastroenterology Department, Valencia, Spain, 11Hospital Clínico Universitario de Santiago, Department of Gastroenterology, Santiago de Compostela, Spain, 12Hospital Universitario Cruces, Department of Gastroenterology, Bilbao, Spain, 13Hospital Dr. Josep Trueta, Department of Gastroenterology, Girona, Spain, 14Hospital de Sagunto, IBD Unit, Gastroenterology Section, Sagunto, Spain, 15University of Cardenal Herrera-CEU, Castellón, Spain, 16Hospital Universitario de Burgos, Burgos, Spain, 17Hospital Ramón y Cajal, Department of Gastroenterology, Madrid, Spain

P310: Diagnostic delay: assessment, improvement and outcome consequences in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Vernero*1, D. G. Ribaldone1, M. Astegiano1

1città della salute e della scienza di torino, Torino, Italy

P311: Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study

ECCO '19 Copenhagen

Year: 2019
Authors:

O. J. Adedokun*1, Z. Xu1, C. Marano1, C. D. O'Brien1, P. Szapary1, H. Zhang1, J. Johanns1, R. W. Leong2,3, T. Hisamatsu4, G. Van Assche5, S. Danese6, M. T. Abreu7, B. E. Sands8, W. J. Sandborn9

1Janssen Research and Development, LLC, Spring House, USA, 2Concord Hospital, Sydney, Australia, 3Macquarie University Hospital, Sydney, Australia, 4Kyorin University, Tokyo, Japan, 5University of Leuven, Leuven, Belgium, 6Humanitas Research Hospital, Milan, Italy, 7University of Miami Miller School of Medicine, Miami, USA, 8Icahn School of Medicine at Mount Sinai, New York, USA, 9University of California San Diego, La Jolla, USA

P312: Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI

ECCO '19 Copenhagen

Year: 2019
Authors:

B. E. Sands*1, L. Peyrin-Biroulet2, C. Marano3, C. D. O'Brien3, H. Zhang3, J. Johanns4, P. Szapary3, D. Rowbotham5,6, R. W. Leong7,8, R. P. Arasaradnam9, S. Danese10, G. Van Assche11, S. Targan12, W. J. Sandborn13

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Nancy University Hospital, Université de Lorraine, Nancy, France, 3Janssen Research and Development, LLC, Spring House, USA, 4Janssen Research and Development, Spring House, USA, 5Auckland City Hospital, Auckland, New Zealand, 6University of Auckland, Auckland, New Zealand, 7Concord Hospital, Sydney, Australia, 8Macquarie University Hospital, Sydney, Australia, 9Warwick Medical School, University Hospital Coventry, Warwickshire, UK, 10Humanitas Research Hospital, Milan, Italy, 11University of Leuven, Leuven, Belgium, 12Cedars-Sinai Medical Center, Los Angeles, USA, 13University of California San Diego, La Jolla, USA

P313: Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study

ECCO '19 Copenhagen

Year: 2019
Authors:

E. V. Loftus Jr*1, D. T. Rubin2, J. Panes3, D. Pugatch4, W. Zhou4, S. Goteti4, A. Lacerda4, S. Travis5

1Mayo Clinic, Rochester, Minnesota, USA, 2The University of Chicago Medicine, Chicago, Illinois, USA, 3Hospital Clínic Barcelona, Barcelona, Spain, 4AbbVie Inc., North Chicago, Illinois, USA, 5Oxford University Hospitals, Oxford, UK

P314: Long-term fate of the excluded rectum in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Yzet*1, G. Kassim2, N. Nair2, J-F. Colombel2, D. B. Sachar2

1Amiens university hospital, Amiens, France, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA

P315: Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Salas*1, K. M. Grebe2, N. Powell3, J. Panés1, J. W. Davis4, F. Hong4, Y. Pang4, A. A. Suleiman5, K. Wallace4, B. G. Feagan6

1Hospital Clinic Barcelona, Barcelona, Spain, 2AbbVie Inc., Worcester MA, USA, 3Guy's and St Thomas' Hospital, London, UK, 4AbbVie Inc., Chicago, IL, USA, 5AbbVie Inc., Ludwigshafen am Rhein, Germany, 6University of Western Ontario, London, ON, Canada

P316: Transanal minimal invasive proctectomy (TaMIP) for perineal Crohn’s disease; a multi-centre prospective cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Chandrasinghe*1,2,3, F. Di Candido4, J. Warusavitarne2,5, A. Spinelli4,6

1St Mark's Hospital, Department of Colorectal Surgery, London, UK, 2Imperial College London, Department of Surgery and Cancer, London, UK, 3University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, 4Humanitas Clinical and Research Center, Division of Colon and Rectal Surgery, Milan, Italy, 5St Mark's Hospital, Department of Gastroenterology, London, UK, 6Humanitas University, Department of Biomedical Sciences, Milan, Italy

P317: Characterisation of patients with delayed response to ustekinumab for Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

B. E. Sands*1, A. Oortwijn2, N. Rijnders2, J. Izanec3, C. Gasink3, D. Jacobstein4, O. J. Adedokun4, T. Ma4, L-L. Gao4, J-F. Colombel5, S. Targan6, S. Ghosh7, W. J. Sandborn8

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Janssen Biologics BV, Leiden, The Netherlands, 3Janssen Scientific Affairs, LLC, Horsham, USA, 4Janssen Research and Development, LLC, Spring House, USA, 5Icahn School of Medicine at Mt Sinai, New York, USA, 6Cedars-Sinai Medical Center, Los Angeles, USA, 7University of Birmingham, Birmingham, UK, 8University of California San Diego, La Jolla, USA

P318: Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Gadhok*1, R. Rao1, S. Honap2, M. Samaan3, L. Harpham-Lockyer3, H. Kwok3, L. Whitley3, A. Ibarra1, N. Burgess1, E. Seward3, G. Parkes1, S. Mehta3, R. Vega3, S. McCartney3, S. Bloom3, P. Irving2, J. O. Lindsay1, K. Kok1, F. Rahman3

1The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, UK, 2Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, UK, 3University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, UK